SCHEMBL11424224

SCHEMBL11424224

CN(Cc1cccc(-c2cnc(C(=O)NC3CCN(Cc4ccccc4)CC3)nc2)c1)C(=O)CNC(=O)OC(C)(C)C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP30 Q70CQ3 1/20 0.49
▸ PRKAA2 P54646 4/20 0.46
▸ MAOB P27338 1/20 0.45
▸ TP53 P04637 3/20 0.45
▸ AOC3 Q16853 6/20 0.44
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ PRKAB2 O43741 1/20 0.43
▸ PRKAG1 P54619 1/20 0.43
▸ PRKAA1 Q13131 1/20 0.43
▸ PRKAG3 Q9UGI9 1/20 0.43
▸ PRKAG2 Q9UGJ0 1/20 0.43
▸ PRKAB1 Q9Y478 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ MCHR1 Q99705 1/20 0.42
▸ SLC6A12 P48065 1/20 0.42
▸ DRD2 P14416 1/20 0.42
▸ DRD4 P21917 1/20 0.42
▸ BCHE P06276 1/20 0.42
▸ ACHE P22303 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11422780 0.87 AOC3 (0.58) PRKAA2AOC3
SCHEMBL12814180 0.85 USP30 (0.49) USP30PRKAA2MAOBTP53MEN1
SCHEMBL11421859 0.84 DRD2 (0.60) MCHR1DRD2DRD4
SCHEMBL11366530 0.84 KMT2A (0.52) AOC3KMT2AMCHR1DRD2DRD4
SCHEMBL11422630 0.83 HTR5A (0.52) MAOBAOC3MEN1KMT2AMCHR1
SCHEMBL19496872 0.83 PRKAA2 (0.54) PRKAA2MAOBMEN1KMT2APRKAB2
SCHEMBL11360217 0.81 AOC3 (0.47) AOC3
SCHEMBL11357938 0.81 CHRM4 (0.49) USP30AOC3ACHE
SCHEMBL11419626 0.81 HDAC3 (0.51) AOC3BCHEACHE
SCHEMBL11421881 0.80 AOC3 (0.46) USP30PRKAA2AOC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2479165-B1 GLYCINE COMPOUND ASTELLAS PHARMA INC (JP) 2017-10-25 — — EP disclosed
US-8802679-B2 Glycine compound ASTELLAS PHARMA INC. (JP) 2014-08-12 — — US disclosed
US-20120184520-A1 GLYCINE COMPOUND ASTELLAS PHARMA INC. (JP) 2012-07-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184520-A1 GLYCINE COMPOUND SLC5A1, AQP1, VAPB USP30 4182/4885PRKAA2 4540/4885MAOB 3939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback